EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE


LinkedIn facebook twitter youtube
News archive

 

ASH 2019 – Orlando. The big “late-breaking” news at the American Society of Hematology Annual Meeting are the results of the phase III Candor trial. Dr Katja Weisel, University Medical Center Hamburg-Eppendorf in Germany, explains for Myeloma Patients Europe (MPE) in this video the main results of this clinical trial.

 







Recent news

» CAR-T cell therapy in myeloma

» Daratumumab subcutaneous, first approved treatment for newly diagnosed AL amyloidosis in Europe

Leave a Reply

Your email address will not be published. Required fields are marked *

I accept the Privacy Policy * for Click to select the duration you give consent until.